Abstract
The antiapoptotic protein myeloid cell leukemia sequence 1 (MCL-1) is highly expressed in many human cancers and has been implicated in the development of resistance to anti-cancer therapy. AMG 176 is a novel, selective, small molecule MCL-1 inhibitor. Here we report preliminary results from a phase 1, first-in-human trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and efficacy of AMG 176 in relapsed or refractory multiple myeloma (RRMM).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
